Publication date: Sep 01, 2024
Mucosal vaccination strategies are easier to implement than others in large-scale poultry farming. However, the adjuvants that are approved for veterinary use, which are predominantly aluminum- and oil-emulsion-based adjuvants, are not suitable for mucosal vaccination and carry a risk of adverse reactions. In this study, we engineered a novel Lactobacillus plantarum NC8 strain that co-expresses chicken interleukin-2 (IL-2) and IL-17B, which we designated NC8-ChIL2-17B, and evaluated its potential as an oral immunoadjuvant. The immunomodulatory properties of NC8-ChIL2-17B were evidenced by its ability to activate macrophages and inhibit the proliferation of infectious bronchitis virus (IBV) in vitro. We then confirmed its immunoadjuvant activity in vivo by orally administering NC8-ChIL2-17B along with a commercial IBV vaccine to chicks. The results indicated that NC8-ChIL2-17B enhanced the immune response elicited by the IBV vaccine and increased the levels of IBV-specific IgG and sIgA antibodies produced in response to IBV infection. Additionally, administration of NC8-ChIL2-17B promoted weight gain and beneficially modulated the gut microbiota, resulting in improved chicken performance. These findings suggest that oral administration of NC8-ChIL2-17B is a promising strategy to enhance the immune efficacy of the IBV vaccine in chickens, offering an efficacious alternative adjuvant.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Lactobacillus plantarum |
| disease | MESH | bronchitis |
| disease | VO | vaccine |
| disease | VO | vaccination |
| drug | DRUGBANK | Aluminium |
| disease | VO | Infectious bronchitis virus |
| disease | IDO | immune response |
| disease | MESH | infection |
| disease | MESH | weight gain |
| disease | MESH | Coronavirus Infections |
| disease | MESH | Poultry Diseases |